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Evaluation of functionalized mesoporous silica
SBA-15 as a carrier system for Ph3Sn(CH2)3OH
against the A2780 ovarian carcinoma cell line†
Christian Bensing,‡a Marija Mojić,‡b Santiago Gómez-Ruiz,*c Sandra Carralero,c
Biljana Dojčinović,d Danijela Maksimović-Ivanić,b Sanja Mijatovićb and
Goran N. Kaluđerović*e
SBA-15|Sn3, a mesoporous silica-based material (derivative of SBA-15) loaded with an organotin com-
pound Ph3Sn(CH2)3OH (Sn3), possesses improved antitumor potential against the A2780 high-grade
serous ovarian carcinoma cell line in comparison to Sn3. It is demonstrated that both the compound and
the nanostructured material are internalized by the A2780 cells. A similar mode of action of Sn3 and
SBA-15|Sn3 against the A2780 cell line was found. Explicitly, induction of apoptosis, caspase 2, 3, 8 and
9 activation, accumulation of cells in the hypodiploid phase as well as accumulation of ROS were
observed. Interestingly, Sn3 loaded in the mesoporous silica-based material needed to reach a concen-
tration 3.5 times lower than the IC50 value of the Sn3 compound, pointing out a higher eﬀect of the
SBA-15|Sn3 than Sn3 alone. Clonogenic potential, growth in 3D culture as well as mobility of cells were
disturbed in the presence of SBA-15|Sn3. Such behavior could be associated with the suppression of p-38
MAPK. Less profound eﬀect of Sn3 compared to SBA-15|Sn3 could be attributed to a diﬀerent regulation
of p-38 and STAT-3, which are mainly responsible for an appropriate cellular response to diverse stimuli
or metastatic properties.
Introduction
One of the most interesting fields of modern nanomedicine is
related to nanoparticles eﬃcient in hosting, protecting, carry-
ing and releasing therapeutic agents at target tissues.1–3 In
2001, mesoporous silica nanoparticles (MSNs) were suggested,
by the group of M. Vallet-Regi, as an interesting drug release
system.4 Since then many researchers have shown growing
interest in MSNs due to their innovative potential in nano-
medicine.1 MSNs can be prepared in various sizes and shapes,
can survive in severe milieu and have various regular pore
sizes.5 Furthermore, the pore diameter can be altered to pre-
serve diverse substances (2–50 nm) enabling their transpor-
tation.6 Such pores can adopt various biomaterials of diﬀerent
nature, from small molecules to proteins, among others, in
relatively large amounts.7,8
MSNs and other silica-based materials, non-toxic to cells,9
are assumed as extraordinary particles in quite a few fields of
medicine such as bone regeneration, for example, however, in
cancer treatment not many investigations have been reported
until now.10–13 An interesting property of this kind of material
is that they favourably accumulate in solid tumours due to the
increased permeation and retention eﬀect.14,15
From our pioneering work, which began in 2009, it is
revealed that MSNs and other silica-based materials such as
SBA-15 and MCM-41 do not aﬀect tumor cell lines at high con-
centrations, up to 1 mg mL−1.16–18 In contrast, the same kind of
material loaded with titanocene compounds enhances the cyto-
toxicity in tumor cells, depending on the particle type (SBA-15
or MCM-41), the titanium(IV) complex as well as its loaded
amount. Moreover, SBA-15 was found to be superior to MCM-41
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as a carrier system. Recently, we reported on a SBA-15 derivative
loaded with Ph3Sn(CH2)6OH observing that this material was
ca. 150 times more active than SBA-15 loaded with titanium(IV)
complexes.19 The strong therapeutic potential of organotin(IV)-
loaded mesoporous silica lies in the development of a nonproli-
ferative melanocyte-like phenotype of surviving cells. Thus, this
nonaggressive suppression of tumor growth with nontoxic
doses of the drug, much lower than the IC50 concentration of
Ph3Sn(CH2)6OH, is highly eﬃcient against melanoma cells.
Contrarily to the induction of apoptosis as the most employed
conventional approach in oncotherapy, this mode of action has
numerous advantages.20 One of them is avoiding the compensa-
tory proliferation phenomenon presents in tumors in response
to cell death in the neighborhood.21
As one of the most lethal gynecological malignancies and the
fifth leading cause of death in women,21 there are more than
100 000 instances of ovarian cancer worldwide each year.22
From the epithelial ovarian cancer, four major histological sub-
types are identified.23,24 Namely, serous, endometrioid, clear cell
and mucinous carcinoma from which the serous type is respon-
sible for ca. 70% of epithelial ovarian cancers. Furthermore,
high-grade serous ovarian carcinoma (HGSOC) is considered as
the most aggressive subtype causing around 70% of all ovarian
cancer deaths.25 The A2780 cell line belongs to the most preva-
lent subtype of HGSOC, besides CAOV3, SK-OV-3, IGROV1 and
OVCAR-3 cells.26 Most patients, after radical surgery and
primary excessive response to platinum- and taxane-based
chemotherapy, face a relapse of HSGOC with a survival of only
18 months.25 As a consequence, the development of novel drugs
is of high importance in order to advance current therapies.
Herein we report the preparation and characterization of the
organotin(IV) compound Ph3Sn(CH2)3OH (Sn3) which has been
grafted onto functionalized SBA-15 to give SBA-15|Sn3.
Furthermore, Sn3 and SBA-15|Sn3 have been tested against
A2780, A549 and DLD-1 tumor cell lines. A2780, as a model of
HGSOC,23 was chosen for the evaluation of the Sn3 and SBA-15|
Sn3 mechanism of action. This cell line overexpressed multidrug
resistant pumps and therefore is an ideal model system for the
assessment of acquired resistance to chemotherapeutics drugs.27
It is well known that metal-based drugs belong to the group of
the most sensitive compounds for eﬄux by the pumps.28 On the
other hand, compounds loaded in MSNs and other silica-based
materials accumulate into the cells due to the down regulation
of transporters as well as bypass the eﬄux action by MSNs them-
selves.29 Therefore, it was of interest to compare the eﬀectiveness
and the mechanism of action of the Ph3Sn(CH2)3OH (Sn3) com-
pound in the free and loaded, SBA-15|Sn3, form. Thus, the influ-
ence on the cell death, metastatic properties of the cell and intra-
cellular response were estimated.
Experimental
Materials and methods
All manipulations for the synthesis of the tin compound and
the functionalized materials were performed under dry nitro-
gen gas using standard Schlenk techniques and a glove box.
Solvents were distilled from the appropriate drying agents and
degassed before use. 3-Chloropropyltriethoxysilane (CPTS) was
purchased from Sigma-Aldrich and used directly without
further purification.
1H, 13C and 119Sn NMR spectra for Sn3 were recorded on a
Varian Gemini 400 and 13C CP/MAS NMR, 29Si MAS NMR and
119Sn MAS NMR spectra were recorded on a Varian-Infinity
Plus Spectrometer at 400 MHz. 13C CP/MAS NMR (4.40 μs 90°
pulse, spinning speed of 6 MHz, pulse delay 2 s), 29Si MAS
NMR (8 μs 90° pda, spinning speed of 6 MHz, pulse delay
10 s), 119Sn MAS NMR (8 μs 90° pda, spinning speed of 6 MHz,
pulse delay 10 s) and the X-ray diﬀraction (XRD) pattern of
silica were obtained on a Phillips Diﬀractometer model
PW3040/00 X′Pert MPD/MRD at 45 kV and 40 mA, using a
wavelength of Cu Kα (λ = 1.5418 Å). MS (ESI) spectra were
recorded on a Finnigan MAT TSQ 7000 (voltage 4.5 kV, sheath
gas nitrogen) instrument. C, H and N elemental microanalyses
were carried out with a CHNS-932 (LECO) elemental analyzer
(Sn3), in the Microanalytical Laboratory of the University of
Halle. N2 gas adsorption–desorption isotherms were obtained
using a Micromeritics ASAP 2020 analyzer. Scanning electron
micrography and morphological analysis were carried out on
an XL30 ESEM Phillips with an energy dispersive spectrometry
system (EDS). The samples were treated with a sputtering
method with the following parameters: sputtering time 100 s,
sputter current 30 mA, film thickness 20 nm using a Sputter
coater BAL-TEC SCD 005. Conventional transmission electron
microscopy (TEM) was carried out on a TECNAI 20 Phillips,
operating at 200 kV. SBA-15 and SBA-15p (Table 1) were pre-
pared as described previously.19
Synthesis of Ph3Sn(CH2)3OH (Sn3)
Ph3SnH (5.86 g, 16.7 mmol), allyl alcohol (2.8 mL, 33.4 mmol)
and AIBN (0.14 mg, 0.8 mmol) were stirred for 3 h at 80 °C.30
The precipitated product was collected, dried under vacuum
and subsequently recrystallized two times from petroleum
ether. The mother liquor was concentrated and purified by
column chromatography (eluent: petroleum ether : CHCl3 =
2 : 1, afterwards ether) and recrystallized from n-hexane. Yield:
4.43 g (64.9%); colorless needles; MP: 104–105 °C; MS (ESI):
m/z = calc. [C21H22OSn–H
+]− 410.1, found: 409.4; elemental
analysis (in %): calc. for C21H22OSn: C 61.65, H 5.42, found:
C 61.57, H 5.27; 1H NMR (CDCl3, 400 MHz): δ (in ppm) = 1.26
(t, 3J (H,H) = 5.48 Hz, 1H; OH), 1.49–1.55 (m, 2H; C1H2), 1.98
Table 1 Textural and chemical properties of synthesized materials
SBA-15, SBA-15p and SBA-15|Sn3 calculated from N2-adsorption–
desorption isotherms, XRD and XRF analysis
Surface
d100
[nm]
a0
[nm]
SBET
[m2 g−1]
Vm
[cm3 g−1]
DP
[nm]
Wd
[nm]
SBA-15 9.22 10.65 932 0.94 4.97 5.68
SBA-15p 9.48 10.91 535 0.58 4.88 6.03
SBA-15|Sn 9.27 10.70 417 0.49 4.88 5.82
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(m, 2H; C2H2), 3.65 (m, 2H; C
3H2), 7.37 (m, 9H; Ar-Hm und
Ar-Hp), 7.56 (m, 6H; Ar-Ho);
13C NMR (CDCl3, 101 MHz): δ (in
ppm) = 6.7 (C1, 1J (119Sn,C) = 397.1 Hz), 29.3 (C2, 2J (117/119Sn,
C) = 21.2 Hz), 65.6 (C3, 3J (119Sn,C) = 66.3 Hz), 128.5 (Cm,
3J (119Sn,C) = 48.8 Hz), 128.9 (Cp,
4J (117/119Sn,C) = 11.0 Hz), 137.0
(Co,
2J (119Sn,C) = 36.1 Hz), 138.9 (Ci,
1J (119Sn,C) = 491.6 Hz);
119Sn NMR (CDCl3, 149 MHz): δ (in ppm) = –99.3 (s, Ph3Sn).
Preparation of SBA-15|Sn3
A solution of 3-(triphenylstannyl)propan-1-ol (0.315 g,
0.77 mmol) in toluene (100 mL) was added to SBA-15p (1.00 g).
Subsequently, triethylamine (75 mg, 0.92 mmol) was added
and the mixture was stirred for 48 h at 80 °C. The slurry was
filtered through a frit and the solid residue was washed with
toluene (3 × 30 mL), hexane (3 × 30 mL), water : ethanol (1 : 1,
2 × 20 mL) and diethylether (2 × 60 mL). The resultant solid
was dried under vacuum at room temperature for 24 h to give
a white free flowing powder. 29Si MAS NMR: δ (in ppm) = –113
(br, s; including Q4 [Si(OSi)2(OH)], Q
3 [Si(OSi)2(OH)], Q
2
[Si(OSi)2(OH)2]), −73 to −62 (br, [SiO–Si(OEt)n(CH2CH2CH2Cl)];
n = 0–1). 13C CP/MAS NMR: δ (in ppm) = 4.3 (CH2–Sn and
CH2–Si), 11.4 (CH2 of CPTS), 18.1 and 31.2 (CH2 of Sn-contain-
ing fragment), 24.6 (CH3 of Et), 45.0 (O–CH2 of Et), 51.7
(O–CH2 of Sn-containing fragment), 126.7 and 134.5 (Ph);
119Sn MAS NMR: δ (in ppm) = –105 ppm. %Sn (obtained by
X-ray fluorescence) = 4.35%. Textural parameters of the
synthesized surface obtained by N2-adsorption–desorption iso-
therms: BET-surface: 417 m2 g−1, pore volume: 0.49 cm3 g−1,
pore size: 4.88 nm and wall thickness: 5.82 nm.
Reagents and cells
Fetal calf serum (FCS), RPMI-1640, phosphate-buﬀered saline
(PBS), dimethyl sulfoxide (DMSO), sulforhodamine (SRB) and
propidium iodide (PI) were obtained from Sigma (St Louis,
MO). Annexin V-FITC (AnnV) was obtained from Santa Cruz
Biotechnology (Dallas, TX). Human ovarian A2780 cell line was
a kind gift from Thomas Miller (Institute for Oncology, Martin
Luther University Halle-Wittenberg). Matrigel™ Basement
Membrane Matrix was purchased from BD Biosciences. The
cells were regularly propagated in HEPES-buﬀered
RPMI-1640 medium supplemented with 10% FCS, 2 mM
L-glutamine, 0.01% sodium pyruvate and antibiotics (culture
medium) at 37 °C under a humidified atmosphere with 5%
CO2. The cells were seeded at 1 × 10
3 – 2.5 × 103 cells per well
in 96-well plates for viability determination and 2.5 × 105 cells
per well in 6-well plates for flow cytometry.
Preparation of drug solutions
Sn3 was dissolved in DMSO at 20 mM and kept at −20 °C until
use. The SBA-15|Sn3 stock (1 mg mL−1) was suspended in
culture medium directly before use. Immediately before the
treatment various working solutions were prepared in culture
medium.
Sulforhodamine test (SRB)
A2780, A549 and DLD-1 cells were seeded at 1000, 2500 and
2000 cells, respectively, per well density and treated with a wide
range of doses of Sn3 or SBA-15|Sn3 for 96 h. At the end of culti-
vation the SRB test was performed exactly as described.31
Morphological analysis (AO/EB double staining)
Sn3 or SBA-15|Sn3 induced cell death in A2780 ovarian tumor
cells was determined using acridine orange (AO) and ethidium
bromide (EB), double staining according to standard pro-
cedures and examined under a fluorescence microscope.33
A2780 cells were seeded overnight on 8 chamber slides (6000
cells per chamber) in 400 µL of complete medium. The next
day, the cells were treated with 2 × IC50 or 2 × MC50 of Sn3 or
SBA-15|Sn, respectively, for 24 h. After this period, the cells on
the slides were stained with an acridine orange/ethidium
bromide mixture (3 μg mL−1 AO and 10 μg mL−1 EB in PBS),
and visualized under a fluorescence microscope (Carl Zeiss).
Caspase 2, 3, 8 and 9 enzyme activity assays
The activity of caspases 2, 3, 8 and 9 was measured using the
caspase substrate cleavage assay. A2780 cells were seeded at a
density of 1 × 106 cells per well in a 6 well plate. After exposure
to an IC50 or MC50 concentration of Sn3 or SBA-15|Sn3, the
cells were sampled after 2 h for the cleavage of caspases. The
adherent cells were washed with cold PBS, collected with a cell
scraper, and suspended in cell lyses buﬀer (50 mM HEPES pH
7.4, 1% Triton X100, all from Sigma-Aldrich). After incubation
for 10 min on ice and centrifugation, protein concentrations
of the supernatants were measured according to a method of
Bradford (Bio-Rad Laboratories). The samples (50 μg protein
extract) were incubated on a microplate at 37 °C overnight in
reaction buﬀer (50 mM HEPES pH 7.4, 0.1% CHAPS, 5 mM
EGTA, 5% glycerol) containing 10 mM DTT (all from Sigma-
Aldrich) and a specific substrate of caspases. The extinction of
released p-nitroaniline was measured at 405 nm using a 96
well plate reader (Tecan Spectra) and the activity of caspases 2,
3, 8 and 9 was evaluated by the OD ratio of treated/untreated
samples.32,34
ICP-MS analysis
For drug uptake experiments the A2780 cells (1.2 × 106) were
seeded in the flask. After 24 h the cells were treated with an
IC50 or MC50 dose of Sn3, SBA-15|Sn3 or SBA-15p (10 mL) for
24 h. Afterwards the cells were washed with PBS (4 mL) and
trypsinized (1 mL). The cells were resuspended in PBS (4 mL)
and centrifuged (5000 U min−1, 5 min). The cell pallet was
washed two times with PBS (1 mL). The lyophilised cells were
Paper Dalton Transactions
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analysed by ICP-MS (Wessling Laboratorien GmbH, Oppin,
Germany).
For Sn3 release study SBA-15|Sn3 (2.0 mg) was suspended
in complete medium (1 mL), for each time point, and the tin
content was investigated by ICP-MS after 0.08, 2, 4, 6, 24 and
72 h, in triplicate. Explicitly, after soaking at 37 °C suspensions
were centrifuged (5000 U min−1) and supernatants were used
for analysis. The liquid samples were diluted with purified
water (1 : 100, v/v). The Thermo Scientific iCAP Qc ICP-MS
instrument was optimized for optimum performance in stan-
dard mode using the supplied autotune protocols. The ICP-MS
instrument was tuned using a solution of TUNE B iCAP Q
(1 μg L−1 of each: Ba, Bi, Ce, Co, In, Li, U) provided by the
manufacturer Thermo Scientific, Germany. External standards
for the instrument calibration were prepared on the basis of a
tin plasma standard solution (Specpure®, Sn 100 µg mL−1
certified reference solution ICP Standard purchased from Alfa
Aesar GmbH & Co KG, Germany). For extracts, the limit of
quantitation (LOQ) for tin was determined to be 2.02 ng L−1.
The measurement was performed on the isotope 120Sn.
Cell cycle analysis
The cells were incubated with an IC50 or MC50 dose of Sn3 or
SBA-15|Sn3 for 72 h and cell cycle analysis is performed as pre-
viously described.35
Measurement of ROS
For the detection of reactive oxygen species the redox-sensitive
dye dihydrorhodamine 123 (DHR) was used. The cells were
stained with 1 mM DHR for 20 min before treatment with an
IC50 or MC50 dose of Sn3 or SBA-15|Sn3. After 48 h the cells
were trypsinized, washed in PBS, and the fluorescence inten-
sity was analysed with a CyFlow® Space Partec using
PartecFloMax® software (Partec GmbH, Münster, Germany).
Cell clonogenic survival assay
The cells were pretreated for 72 h with an IC50 or MC50 dose of
Sn3 or SBA-15|Sn3, then detached, counted and 1000 cells per
well were reseeded. The cells were grown for 5 days without
changing the medium. After 9 days of cultivation, colonies
were fixed with 4% PFA for 30 min at RT and then stained for
30 min at RT with 0.25% 1,9-dimethyl methylene blue in 50%
ethanol. Finally, the colonies were washed twice with PBS and
analyzed by light microscopy. The plate eﬃciency (PE) is calcu-
lated as the number of colonies/number of cells × 100, while
the surviving fraction is calculated as PE of treatment/PE of
control × 100.
Adhesion assay
96 well plates were covered with Matrigel 10 µg mL−1 at 4 °C
overnight. The wells were washed 3 times with PBS before
seeding the cells. The cells were pretreated for 72 h with an
IC50 or MC50 dose of Sn3 or SBA-15|Sn3, then detached,
counted and left for approximately 30 min for membrane
reconstitution. Then, 30 000 cells per well are allowed to
adhere to Matrigel for 1 h. Nonadherent cells were then
washed with 3× PBS, fixed with 4% PFA, and stained with
crystal violet for 15 min at RT. The cells were washed with tap
water, and the dye was dissolved in 33% acetic acid.
Absorbance was measured at 570 nm and the results are calcu-
lated as the percentage of control nontreated cells.
Transmigration assays
The cells were pretreated for 72 h with an IC50 or MC50 dose of
Sn3 or SBA-15|Sn3, and then detached, counted and 2 × 105
cells were seeded in Transwells (membrane pore size, 8 mm;
diameter, 6.4 mm; BD Biosciences Discovery Labware)
assembled in 24-well plates in 0.1% BSA-RPMI. As a chemo-
attractant for the cells, the lower chambers were filled up with
10% fetal calf serum-RPMI 1640 medium. The cells were
allowed to migrate for 24 h. The cells that failed to migrate
remained on the upper surface and were carefully removed
with a cotton swab while the cells on the lower surface of the
membranes were fixed with 4% PFA and stained with Mayer’s
hematoxylin (BioOptica, Milan, Italy). The cells were counted
under a light microscope at 40× magnification using the new
computer-assisted CAST integrator system (Visiopharm,
Hoersholm, Denmark). The average number of cells attached
to the lower surface in 30 independent fields (200 mm ×
200 mm) per membrane is presented. Each experiment was
performed in triplicate.
Western blot analysis
A2780 cells were cultivated with an IC50 or MC50 dose of Sn3 or
SBA-15|Sn3 for 6,12, 24 and 48 h and lysed in protein lysis
buﬀer (62.5 mM Tris–HCl (pH 6.8 at 25 °C), 2% (w/v) SDS,
10% glycerol, 50 mM dithiothreitol). Electrophoretical separ-
ation of proteins was performed on 10–12% SDS-polyacryl-
amide gels. Electrotransfer to polyvinylidene difluoride mem-
branes at 5 mA cm−2 was accomplished with a semidry blot-
ting system (Fastblot B43; BioRad, Göttingen, Germany).
Blocking of membranes was done with 5% (w/v) BSA in PBS.
The membranes were incubated overnight at 4 °C with specific
antibodies to phospho-Akt, Akt, phospho-p44/p42 MAPK
(Erk1/2)(Thr202/Tyr204), p44/p42 MAPK (Erk1/2), phospho-p38
MAPK (Thr180/Tyr182), p38 MAPK, and STAT3 (Cell Signaling
Technology, Danvers, MA. USA), and Actin (Abcam,
Cambridge, UK). Goat anti-rabbit IgG-HRP (Santa Cruz
Biotechnology, Dallas, TX, USA) was used as a secondary anti-
body. Bands were detected with the chemiluminescence detec-
tion system (ECL; GE Healthcare, Chalfont St. Giles,
Buckinghamshire, UK).
Results and discussion
Preparation and characterization
The syntheses of Ph3Sn(CH2)3OH (Sn3) as well as SBA-15 and
SBA-15p were performed according to the literature pro-
cedures.19,30 SBA-15 was synthesized by a sol–gel method and sub-
sequently calcined. SBA-15p was obtained by functionalization of
dehydrated SBA-15 surfaces with 3-chloropropyltriethoxysilane
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(CPTS), in a subsequent step Sn3 was loaded into SBA-15p
(SBA-15|Sn3) in the presence of triethylamine.
A uniform morphology of MSN particles was observed by
SEM and TEM analysis. Thus, images revealed nanostructured-
rod shaped particles with a particle size of ca. 670 nm in
length and ca. 440 nm in width (calculated from the SEM data)
and a uniform pore size with hexagonal distribution (Fig. 1).
SEM and TEM images of SBA-15p and SBA-15|Sn3 particles
did not demonstrate any substantial alteration to SBA-15 par-
ticles indicating that the morphology of the MSNs was not
aﬀected after chemical modification (SBA-15p) nor adsorption
(SBA-15|Sn3).
The physical parameters of nitrogen adsorption–desorption
isotherms, BET surface area, average pore diameter, average
pore volume, and wall thickness were measured for all the
materials. Thus, nitrogen adsorption–desorption analysis of
SBA-15|Sn3 showed a type IV isotherm36 indicating the meso-
porous nature of materials. As expected, the pore diameter as
well as the surface area of MSNs are aﬀected after subsequent
functionalization steps of SBA-15.
Explicitly, a uniform pore diameter of 4.97, 4.88 and
4.88 nm, calculated by the BJH method,37 and a high BET
surface of 932, 535 and 417 m2 g−1 (SBET) for SBA-15, SBA-15p
and SBA-15|Sn3, respectively, were found. In addition, the wall
thickness in materials from SBA-15, SBA-15p to SBA-15|Sn3
(5.68 → 6.03) increased after the first functionalization and
remained almost the same (5.82 nm, if not somewhat higher)
after the second functionalization.
This indicates that, in the first reaction (with CPTS), the
functionalization takes place mainly inside the pore of the
nanostructured material, while in the second modification the
incorporation of the tin compound may be both in the pore
and onto the external surface area.
SBA-15 demonstrated a well-resolved pattern at low 2θ values
with a very sharp (100) diﬀraction peak at 0.958. This system
can be indexed as a hexagonal lattice with a d-spacing value of
92.2. The X-ray diﬀraction pattern (XRD) of the SBA-15p as well
as SBA-15|Sn3 materials also exhibited reflections typical of
hexagonally ordered mesoporous materials (2θ = 0.920 and
0.953; d = 94.8 and 92.7 for SBA-15p and SBA-15|Sn3, respect-
ively).18 X-ray fluorescence spectroscopy revealed a functionali-
zation rate of 4.35% (w/w) of Sn per gram of material.
Grafting of SBA-15p was furthermore confirmed by 13C CP/
MAS NMR and 119Sn MAS NMR spectroscopy. In addition to
the pattern of the chemical shifts observed in the 13C CP/MAS
NMR spectrum of SBA-15|Sn3 the appearance of a set of
signals related to methylene and phenyl carbon atoms of the
Sn3 was detected. In the 119Sn MAS NMR spectrum, a singlet
arising from the Sn from the tetraorganotin(IV) compound
(−105 ppm) corresponds to Sn3 (−99.3 ppm in CDCl3).
Cytotoxicity and mechanism of action of SBA-15|Sn3 against
the A2780 cell line
The in vitro anticancer activity of Sn3, SBA-15p and SBA-15|Sn3
was investigated against the ovarian A2780, lung A549 and colon
DLD-1 tumor cell lines with the SRB assay.38 The IC50 and MC50
values along with those of cisplatin are presented in Table 2.
The activity of SBA-15p materials was found to be inactive
under the investigated conditions, which is in accordance with
previous results.19 Depending on the cell line the Sn3 com-
pound exhibits lower (A2780, A549) or higher activity (DLD-1)
than cisplatin. The amount of Sn3 (4.35%) in an MC50 concen-
tration of SBA-15|Sn3 material is similar to that of the IC50
dose of free Sn3. However, its activity is in the same concen-
tration range as previously reported for analogous MSNs con-
taining hexyl (Ph3Sn(CH2)6OH) instead of a propyl spacer
(Ph3Sn(CH2)3OH) in the organotin(IV) compound.
19 In
addition, the activity of the SBA-15|Sn3 material is at least 150
times higher than that of the most active titanocene
Fig. 1 (A) SEM and (B) TEM images of SBA-15|Sn3.
Table 2 Cytotoxic potential of Sn3 and SBA-15|Sn3
Compound/material A2780 A549 DLD-1
Cisplatin IC50 ± SD [μM] 0.6 ± 0.1 1.5 ± 0.1 5.1 ± 0.2
Sn3 2.8 ± 0.1 3.8 ± 0.1 3.7 ± 0.1
SBA-15|Sn3 2.6 ± 0.5 2.5 ± 0.1 3.5 ± 0.1
MC50 ± SD [μg mL−1] 7.2 ± 1.4 6.8 ± 0.1 9.7 ± 0.2
SBA-15p >500
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compound, [Ti{Me2Si(η5-C5Me4)(η5-C5H4)}Cl2], grafted into
SBA-15 (MC50 = 309 ± 42 µg mL
−1), from the previous study.16
The diminished viability of A2780 cells after exposure to
Sn3 or SBA-15|Sn3 was connected with the induction of apop-
totic cell death. In order to evaluate the apoptotic process,
double Ann-PI staining was performed (Fig. 2A).
An intensified percentage of both early and late apoptotic
A2780 cells upon 72 h of treatment with SBA-15|Sn3 in com-
parison to Sn3 was detected (Fig. 2A). Morphological changes
of apoptotic cells, such as nuclei shrinkage as well as conden-
sation and/or fragmentation of the DNA, are observed in the
A2780 cells treated with Sn3 or SBA-15|Sn3 (Fig. 2B).
The amount of activated caspases detected was pro-
portional to the apoptosis intensity in both cultures (Fig. 2C).
Moreover, it could be clearly observed that the activation of
caspase initiators 2, 8 and 9 as well as caspase executor 3
upon treatment of the A2780 cells occurs after 24 h of treat-
ment with the free as well as loaded Sn3 compound.
Thus, a certain amount of Sn3 is released from the nano-
material, since MSNs are not capable to interact with the cell
death receptor. In addition to this, analysis of cell cycle distri-
bution (Fig. 2D) showed accumulation of cells in the hypodi-
ploid phase confirming the apoptosis. The presence of cells
with fragmented DNA correlated with the results of Ann/PI
staining. The triggered apoptotic process was well synchro-
nized with the enhanced production of ROS species in cell cul-
tures exposed to both free Sn3 and loaded MSN, suggesting
their involvement in this process (Fig. 2E).
The measurement of the intracellular metal amount by
ICP-MS after 24 h of cultivation indicated that the cells
eﬃciently take up both Sn3 and SBA-15|Sn3 (Fig. 2F).
However, the unexpected ratio of Sn and Si detected in the
cells treated with the nanomaterial SBA-15|Sn3 indicated that
a drug is released also in the extracellular compartment. At
least around 30% of Sn3 found in the cells is not carried by
SBA-15p, thus Sn3 enters in the A2780 cells independently. To
confirm this finding an Sn3 release study from SBA-15|Sn3
under simplified conditions was conducted. Namely, SBA-15|
Sn3 was soaked in the presence of completed medium in
order to obtain desorption behavior of the Sn3 compound
(ICP-MS). In concordance with the uptake study and caspase
activation, the evaluation of Sn3 desorption (see Fig. S7†) veri-
fied the assumption that apart from the MSN loaded form, the
cells are exposed to Sn3 from the extracellular compartment
that might be related to caspase 8 activation as the main sign
of receptor dependent apoptosis. Even under this circum-
stance, previous assessments clearly confirmed that the cells
acquired enough amount of metal-based drug underlining
once more that loading into SBA-15p amplified its tumoricidal
potential. The response of A2780 cells treated with SBA-15|Sn3
is enhanced in comparison to Sn3 alone notwithstanding 3.7
times lower concentration (ICP-MS) of Sn3.
SBA-15|Sn3 decreases proliferative rate and metastatic
properties of A2780 cells
The cells that survived the treatment with Sn3 or SBA-15|Sn3
lost their proliferative potential. Namely, the clonogenic survi-
val assay (Fig. 3A) showed that the colony forming potential of
cells exposed to Sn3 and especially to SBA-15|Sn3 was dramati-
cally abrogated. The plate eﬃciency was 34.3, 20.6, and 3.1 in
control, Sn3 treated and SBA-15|Sn3 treated cells, respectively,
with surviving fractions 100, 60, and 9. In concordance with
Fig. 2 Sn3 and SBA15|Sn3 induced caspase dependent apoptosis. (A) AnnV-FITC/PI double staining; (B) AO/EB double staining; (C) caspase acti-
vation; (D) cell cycle distribution; (E) ROS induction; and (F) Si and Sn uptake by the cells.
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this, the growth rate of the cells pretreated for 72 h with experi-
mental drugs was decreased in comparison to nontreated cells
confirming the permanent change of the cell phenotype sus-
tained even in the absence of the drug (Fig. 3B). The cultiva-
tion of the cells in 3D cultures on Matrigel (Fig. 3C) was com-
promised in the presence of Sn3 and dominantly SBA-15|Sn3.
The number, colony form and communication between them
were disturbed probably as a consequence of both, decreased
dividing potential and mobility of tumor cells. Changed behav-
ior in Matrigel was observed in pretreated cultures suggesting
that 72 h pulse with the drug is enough for permanent repro-
gramming of tumor cells. These results have special importance
in terms that cultivation in 3D cultures more closely resembles
the tumour microenvironment, and therefore are much more
relevant for the estimation of the drug eﬃciency.39
Simultaneously, the aﬃnity of cells to adhere to the extra-
cellular matrix was significantly decreased upon exposure to
both the compound and material (Fig. 3D). Moreover, the
migratory potential of the A2780 cells was dramatically
aﬀected by the tested drugs (Fig. 3E). According to this, it
could be concluded that experimental therapeutics have not
just cytotoxic potential but also capacity to suppress their
metastatic properties.
Diﬀerence in the intracellular molecular background of A2780
cells treated with Sn3 and SBA-15|Sn3
To determine the drugs influence on the major signaling path-
ways responsible for cellular proliferation, diﬀerentiation and
death, western blot analysis of the expression of p-38, Erk1/2
and Akt has been performed (Fig. 4A). One of the crucial tran-
scriptional factors regulating the expression of genes involved
in the growth and apoptosis program in response to diﬀerent
stimuli is STAT3, and therefore its expression was also ana-
lyzed.40 The diﬀerences in the expression of Akt and ERK1/2
between Sn3 and SBA-15|Sn3 treated A2780 cells were not
observed. While the expression of Akt was transiently sup-
pressed, ERK1/2 phosphorylation was remarkably elevated.
Both phenomena are related to the loss of proliferative poten-
tial as well as apoptosis induction. Suppression of Akt even in
transient mode is basically connected with the decreased
dividing rate.41 On the other hand, Erk1/2 activation was
observed in numerous cancer cells in response to chemo-
Fig. 3 Sn3 and SBA-15|Sn3 decreased metastatic properties of A2780 cells. (A) clonogenic survival assay; (B) viability of pretreated cells with Sn3
and SBA-15|Sn3 upon drug removal; (C) the growth in 3D cultures; (D) adhesion; and (E) transmigration test.
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therapy leading to cell death.42,43 Interestingly, the expression
of p-38 is radically changed after grafting Sn3 in SBA-15p.
While its activity is transiently upregulated in cells exposed to
Sn3, decreased phosphorylation was detected after the treat-
ment with SBA-15|Sn3.
Knowing that the activation of the p-38 MAPK pathway
plays a role in invasion and metastasis formation, decreased
expression of this molecule after SBA-15|Sn3 exposure could
be responsible for disturbed Matrigel growth, migration and
adhesiveness of A2780 cells herein.44 It is possible that this
discrepancy in p-38 regulation contributed to improved poten-
tial of Sn3 established upon incorporation to SBA-15p.
A similar pattern of changes in STAT-3 expression was noticed.
Numerous data confirm the positive relation between STAT3
activity and tumorigenesis as well as tumor progression bring
additional explanation for its improved activity of SBA-15|Sn3
in comparison to naked drug Sn3.
Conclusions
Highly invasive cancers are able to establish the resistant
phenotype against diﬀerent chemotherapeutics through
multiple mechanisms. One of the leading between them is the
overexpression of MDR pumps. It overcomes the eﬄux of
Ph3Sn(CH2)3OH (Sn3), silica-based nanostructured materials
were used as a carrier. The loading of Sn3 into SBA-15p con-
served and even potentiated drug eﬀectiveness. The cultivation
of cells in the presence of SBA-15|Sn3 led to a dual influence
of free Sn3 from the extracellular compartment concomitantly
with the internalized MSN form.
The antitumor action of SBA-15|Sn3 in A2780 can be
ascribed to the induction of caspase dependent apoptosis
probably triggered by ROS species. In parallel, the survived
cells displayed a changed phenotype with decreased prolifera-
tive rate and metastatic properties. Diﬀerent intracellular
molecular backgrounds reflected through p-38 and STAT-3
regulation argue a better activity of this metal based drug
applied in the nanocarrier. Altogether, the packaging of Sn3 in
MSN could be considered as a promising strategy for the
improvement of chemotherapeutic application.
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